Helicobacter pylori infection historical perspective: Difference between revisions

Jump to navigation Jump to search
Line 11: Line 11:
*In 1994, the national institute of health (NIH) consensus development panel concluded that there is a strong association between H. pylori and ulcer disease, and recommends that ulcer patients with H. pylori infection be treated with antibiotics.<ref name="pmid8007082">{{cite journal |vauthors= |title=NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease |journal=JAMA |volume=272 |issue=1 |pages=65–9 |year=1994 |pmid=8007082 |doi= |url=}}</ref>
*In 1994, the national institute of health (NIH) consensus development panel concluded that there is a strong association between H. pylori and ulcer disease, and recommends that ulcer patients with H. pylori infection be treated with antibiotics.<ref name="pmid8007082">{{cite journal |vauthors= |title=NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease |journal=JAMA |volume=272 |issue=1 |pages=65–9 |year=1994 |pmid=8007082 |doi= |url=}}</ref>
*In 1994, the International Agency for Research on Cancer (IARC) concluded that ''[[H.pylori]]'' is a group I human carcinogen for gastric adenocarcinoma.<ref name="pmid9103907">{{cite journal |vauthors=Tanida N, Sakagami T, Sawada Y, Shimoyama T |title=[Critical review on the WHO/IARC report regarding carcinogenicity of Helicobacter pylori] |language=Japanese |journal=Nippon Rinsho |volume=55 |issue=4 |pages=995–1002 |year=1997 |pmid=9103907 |doi= |url=}}</ref>
*In 1994, the International Agency for Research on Cancer (IARC) concluded that ''[[H.pylori]]'' is a group I human carcinogen for gastric adenocarcinoma.<ref name="pmid9103907">{{cite journal |vauthors=Tanida N, Sakagami T, Sawada Y, Shimoyama T |title=[Critical review on the WHO/IARC report regarding carcinogenicity of Helicobacter pylori] |language=Japanese |journal=Nippon Rinsho |volume=55 |issue=4 |pages=995–1002 |year=1997 |pmid=9103907 |doi= |url=}}</ref>
*In 1997, FDA approved three H.pylori regimens for the eradication of H. pylori infection. They are<ref name="pmid9394774">{{cite journal |vauthors=Hopkins RJ |title=Current FDA-approved treatments for Helicobacter pylori and the FDA approval process |journal=Gastroenterology |volume=113 |issue=6 Suppl |pages=S126–30 |year=1997 |pmid=9394774 |doi= |url=}}</ref>
:*Regimen 1: Omeprazole+ clarithromycin
:*Regimen 2: Ranitinine-Bismuth-Citrate + Clarithromycin
:*Regimen 3: Bismuth subsalicylate + metronidazole + Tetracycline + an H2 receptor antagonist 





Revision as of 15:40, 15 December 2016

Helicobacter pylori infection Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Gastritis
Peptic ulcer disease
Gastric adenocarcinoma
MALT lymphoma

Causes

Differentiating Helicobacter pylori infection from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Guideline Recommendation

ACG guidelines
ESPGHAN and NASPGHAN guidelines

History and Symptoms

Physical Examination

Diagnostic tests

Endoscopic tests
Nonendoscopic tests

Electrocardiogram

X Ray

CT

MRI

Ultrasound

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Helicobacter pylori infection historical perspective On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Helicobacter pylori infection historical perspective

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Helicobacter pylori infection historical perspective

CDC on Helicobacter pylori infection historical perspective

Helicobacter pylori infection historical perspective in the news

Blogs on Helicobacter pylori infection historical perspective

Directions to Hospitals Treating Helicobacter pylori infection

Risk calculators and risk factors for Helicobacter pylori infection historical perspective

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Yamuna Kondapally, M.B.B.S[2]

Overview

It was identified in 1982 by Barry Marshall and Robin Warren, who found that it was present in patients with chronic gastritis and gastric ulcers, conditions that were not previously believed to have a microbial cause.

Historical Perspective

  • The association between Helicobacter pylori and peptic ulcers was made by Barry Marshall and Robin Warren in the year 1984.[1][2][3][4]
  • In 2005, Barry Marshall and Robin Warren won Nobel prize in physiology or medicine for their "discovery of bacterium Helicobacter pylori and and its role in gastritis and peptic ulcer disease".
  • In 1994, the national institute of health (NIH) consensus development panel concluded that there is a strong association between H. pylori and ulcer disease, and recommends that ulcer patients with H. pylori infection be treated with antibiotics.[5]
  • In 1994, the International Agency for Research on Cancer (IARC) concluded that H.pylori is a group I human carcinogen for gastric adenocarcinoma.[6]
  • In 1997, FDA approved three H.pylori regimens for the eradication of H. pylori infection. They are[7]
  • Regimen 1: Omeprazole+ clarithromycin
  • Regimen 2: Ranitinine-Bismuth-Citrate + Clarithromycin
  • Regimen 3: Bismuth subsalicylate + metronidazole + Tetracycline + an H2 receptor antagonist


1995

Data show that about 75 percent of ulcer patients are still treated primarily with antisecretory medications, and only 5 percent receive antibiotic therapy. Consumer research by the American Digestive Health Foundation finds that nearly 90 percent of ulcer sufferers are unaware that H. pylori causes ulcers. In fact, nearly 90 percent of those with ulcers blame their ulcers on stress or worry, and 60 percent point to diet.

1996

The Food and Drug Administration approves the first antibiotic for treatment of ulcer disease.

1997

The Centers for Disease Control and Prevention (CDC), with other government agencies, academic institutions, and industry, launches a national education campaign to inform health care providers and consumers about the link between H. pylori and ulcers. This campaign reinforces the news that ulcers are a curable infection, and the fact that health can be greatly improved and money saved by disseminating information about H. pylori. Medical researchers sequence the H. pylori genome. This discovery can help scientists better understand the bacterium and design more effective drugs to fight it.

References

  1. Fock KM, Graham DY, Malfertheiner P (2013). "Helicobacter pylori research: historical insights and future directions". Nat Rev Gastroenterol Hepatol. 10 (8): 495–500. doi:10.1038/nrgastro.2013.96. PMC 3973742. PMID 23752823.
  2. Kusters JG, van Vliet AH, Kuipers EJ (2006). "Pathogenesis of Helicobacter pylori infection". Clin Microbiol Rev. 19 (3): 449–90. doi:10.1128/CMR.00054-05. PMC 1539101. PMID 16847081.
  3. "Unidentified curved bacilli on gastric epithelium in active chronic gastritis". Lancet. 1 (8336): 1273–5. 1983. PMID 6134060.
  4. Marshall BJ, Armstrong JA, McGechie DB, Glancy RJ (1985). "Attempt to fulfil Koch's postulates for pyloric Campylobacter". Med J Aust. 142 (8): 436–9. PMID 3982345.
  5. "NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease". JAMA. 272 (1): 65–9. 1994. PMID 8007082.
  6. Tanida N, Sakagami T, Sawada Y, Shimoyama T (1997). "[Critical review on the WHO/IARC report regarding carcinogenicity of Helicobacter pylori]". Nippon Rinsho (in Japanese). 55 (4): 995–1002. PMID 9103907.
  7. Hopkins RJ (1997). "Current FDA-approved treatments for Helicobacter pylori and the FDA approval process". Gastroenterology. 113 (6 Suppl): S126–30. PMID 9394774.

Template:WH Template:WS